Skip to main content

Table 1 Summary of the main features of the currently available tumor necrosis factor alpha inhibitors

From: Update on intravitreal anti-tumor necrosis factor alpha therapies for ocular disorders

Generic name (brand name) Molecular weight (kDa) Mechanism of action Route of administration Half-life (days)
Etanercept (Enbrel) 150 TNF soluble decoy receptor Subcutaneous injection 4 to 6
Infliximab (Remicade) 149 Anti-TNF monoclonal antibody Intravenous infusion 8 to 10
Adalimumab (Humira) 148 Anti-TNF monoclonal antibody Subcutaneous injection 14
Golimumab (Simponi) 150 to 151 Anti-TNF monoclonal antibody Subcutaneous infusion 14
Certolizumab (Cimzia) 91 Pegylated anti-TNF monoclonal antibody Subcutaneous injection 14
  1. kDa, kilodalton; TNF, tumor necrosis factor.